284 related articles for article (PubMed ID: 32919298)
1. Access to cannabidiol without a prescription: A cross-country comparison and analysis.
McGregor IS; Cairns EA; Abelev S; Cohen R; Henderson M; Couch D; Arnold JC; Gauld N
Int J Drug Policy; 2020 Nov; 85():102935. PubMed ID: 32919298
[TBL] [Abstract][Full Text] [Related]
2. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Zenone MA; Snyder J; Crooks V
BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
[TBL] [Abstract][Full Text] [Related]
3. Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.
Hallinan CM; Eden E; Graham M; Greenwood LM; Mills J; Popat A; Truong L; Bonomo Y
J Psychopharmacol; 2022 Jun; 36(6):661-665. PubMed ID: 34344208
[TBL] [Abstract][Full Text] [Related]
4. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
Geppert J; Lietzow J; Hessel-Pras S; Kirsch F; Schäfer B; Sachse B
BMC Public Health; 2023 Nov; 23(1):2318. PubMed ID: 37996800
[TBL] [Abstract][Full Text] [Related]
5. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.
Grafinger KE; Krönert S; Broillet A; Weinmann W
Forensic Sci Int; 2020 May; 310():110261. PubMed ID: 32229319
[TBL] [Abstract][Full Text] [Related]
8. A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products.
Meng Q; Buchanan B; Zuccolo J; Poulin MM; Gabriele J; Baranowski DC
PLoS One; 2018; 13(5):e0196396. PubMed ID: 29718956
[TBL] [Abstract][Full Text] [Related]
9. Combination of UV and MS/MS detection for the LC analysis of cannabidiol-rich products.
Nemeškalová A; Hájková K; Mikulů L; Sýkora D; Kuchař M
Talanta; 2020 Nov; 219():121250. PubMed ID: 32887141
[TBL] [Abstract][Full Text] [Related]
10. Use and Perceptions of Cannabidiol Products in Canada and in the United States.
Goodman S; Wadsworth E; Schauer G; Hammond D
Cannabis Cannabinoid Res; 2022 Jun; 7(3):355-364. PubMed ID: 33998872
[No Abstract] [Full Text] [Related]
11. A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis.
Bawa Z; Saini B; McCartney D; Bedoya-Pérez M; McLachlan AJ; McGregor IS
Int J Clin Pharm; 2023 Apr; 45(2):375-386. PubMed ID: 36446995
[TBL] [Abstract][Full Text] [Related]
12. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
Gurley BJ; Murphy TP; Gul W; Walker LA; ElSohly M
J Diet Suppl; 2020; 17(5):599-607. PubMed ID: 32431186
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
14. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS; Phillips S; ElSohly MA; Walker LA
Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
[TBL] [Abstract][Full Text] [Related]
15. Quality Traits of "Cannabidiol Oils": Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations.
Pavlovic R; Nenna G; Calvi L; Panseri S; Borgonovo G; Giupponi L; Cannazza G; Giorgi A
Molecules; 2018 May; 23(5):. PubMed ID: 29783790
[TBL] [Abstract][Full Text] [Related]
16. An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom.
Liebling JP; Clarkson NJ; Gibbs BW; Yates AS; O'Sullivan SE
Cannabis Cannabinoid Res; 2022 Apr; 7(2):207-213. PubMed ID: 33998849
[No Abstract] [Full Text] [Related]
17. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
18. Availability and Promotion of Cannabidiol (CBD) Products in Online Vape Shops.
Leas EC; Moy N; McMenamin SB; Shi Y; Benmarhnia T; Stone MD; Trinidad DR; White M
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34206501
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.
Arnold JC; McCartney D; Suraev A; McGregor IS
Clin Transl Sci; 2023 Jan; 16(1):10-30. PubMed ID: 36259271
[TBL] [Abstract][Full Text] [Related]
20. Absence of Age Verification for Online Purchases of Cannabidiol and Delta-8: Implications for Youth Access.
Egan KL; Villani S; Soule EK
J Adolesc Health; 2023 Jul; 73(1):195-197. PubMed ID: 36870900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
